ARS Pharmaceuticals, Inc. financial data

Symbol
SPRY on Nasdaq
Industry
Pharmaceutical Preparations
Location
11682 El Camino Real, Suite 120, San Diego, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Silverback Therapeutics, Inc. (to 11/8/2022)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.84K % +5.29%
Debt-to-equity 2.66 % -40.4%
Return On Equity -19.8 % +32.1%
Return On Assets -19.3 % +2.28%
Operating Margin -11.3K % +59.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 96.9M shares +1.44%
Common Stock, Shares, Outstanding 96.9M shares +1.7%
Entity Public Float 382M USD +271%
Common Stock, Value, Issued 10K USD +11.1%
Weighted Average Number of Shares Outstanding, Basic 96.8M shares +2.02%
Weighted Average Number of Shares Outstanding, Diluted 96.8M shares +2.02%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 500K USD +128%
Research and Development Expense 18.5M USD -17.5%
General and Administrative Expense 38.7M USD -1.14%
Operating Income (Loss) -56.7M USD +7.58%
Net Income (Loss) Attributable to Parent -44.8M USD +15.9%
Earnings Per Share, Basic -0.47 USD/shares +38.2%
Earnings Per Share, Diluted -0.47 USD/shares +38.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.6M USD -69.2%
Assets, Current 221M USD -13.4%
Property, Plant and Equipment, Net 636K USD +7.07%
Operating Lease, Right-of-Use Asset 146K USD -58.2%
Other Assets, Noncurrent 690K USD
Assets 222M USD -14.2%
Accounts Payable, Current 3.27M USD +118%
Employee-related Liabilities, Current 2.33M USD -28.9%
Accrued Liabilities, Current 3.65M USD -70.9%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 6.73M USD -33.1%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 6.73M USD -34.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -145K USD +19.4%
Retained Earnings (Accumulated Deficit) -154M USD -41%
Stockholders' Equity Attributable to Parent 215M USD -13.4%
Liabilities and Equity 222M USD -14.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.71M USD +46%
Net Cash Provided by (Used in) Financing Activities 258K USD -80.4%
Net Cash Provided by (Used in) Investing Activities -8.51M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 96.9M shares +1.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -15M USD +87.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36.6M USD -69.2%
Deferred Tax Assets, Valuation Allowance 29M USD +63.6%
Deferred Tax Assets, Gross 29M USD +63.6%
Operating Lease, Liability 160K USD -57.8%
Depreciation 11K USD -45%
Payments to Acquire Property, Plant, and Equipment 83K USD -57%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -44.8M USD +16.3%
Lessee, Operating Lease, Liability, to be Paid 165K USD -59.4%
Property, Plant and Equipment, Gross 748K USD +14.7%
Operating Lease, Liability, Current 160K USD -31.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 42K USD -82.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 123K USD +3.36%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5K USD -81.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 42K USD
Deferred Tax Assets, Operating Loss Carryforwards 16.1M USD +95.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.95M USD +93.8%
Operating Lease, Payments 1.99M USD +14.1%
Additional Paid in Capital 369M USD +3.21%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 29.2M USD +61.9%
Share-based Payment Arrangement, Expense 11.6M USD +20.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%